Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.

Eligibility

Inclusion Criteria:

1. ES-SCLC with confirmed diagnosis of SCLC by histology or cytology
2. Progression during or after prior first or second line chemotherapy. First-line regimen must have been a platinum-containing combination.
3. Measurable or evaluable disease as defined by RECIST v1.1

Exclusion Criteria:

1. History of topotecan (or other topoisomerase I inhibitor) or trilaciclib treatment for SCLC
2. Any chemotherapy, immunotherapy, biologic, investigational, or hormonal therapy for cancer treatment within 3 weeks, except for adjuvant hormonal therapy for breast cancer and prostate cancer
3. Presence of brain metastases/leptomeningeal disease requiring immediate treatment with radiation therapy or steroids
4. Radiotherapy within 2 weeks
5. History of ILD/pneumonitis
6. History of other malignancies, except for curatively treated solid tumors with no evidence of disease for ≥ 2 years or other NCS cancers

Conditions3

Interventions2

Related trials

• A Multi-Arm, Platform Trial For Relapsed Neuroblastoma — University of Birmingham
• A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) — GlaxoSmithKline
• A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer — Qilu Pharmaceutical Co., Ltd.
• ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer — Hansoh BioMedical R&D Company
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors — Gustave Roussy, Cancer Campus, Grand Paris
• HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer — Hansoh BioMedical R&D Company
• High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed — Eye & ENT Hospital of Fudan University
• Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC — Luye Pharma Group Ltd.

Browse More Trials